Hypercalcemia

Current Problems in Surgery

Volumn 39, Issue 4, 2002, Pages 360-447

  Kinder, Barbara K ^a   Stewart, Andrew F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; GALLIUM NITRATE; GLUCOCORTICOID; INDOMETACIN; LITHIUM; MITHRAMYCIN; PAMIDRONIC ACID; PHOSPHORUS; RETINOL; RISEDRONIC ACID; SODIUM CHLORIDE; THIAZIDE DIURETIC AGENT; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ADDISON DISEASE; ARTICLE; BLOOD TOXICITY; CALCIUM HOMEOSTASIS; CANCER; CHEMICAL STRUCTURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; GRANULOMATOSIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; LIVER TOXICITY; NEPHROTOXICITY; OUTCOMES RESEARCH; PARATHYROIDECTOMY; PATHOGENESIS; PREOPERATIVE CARE; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; THYROTOXICOSIS; BLOOD; GENETICS; HOMEOSTASIS; PHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

CALCIUM; HOMEOSTASIS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 0036551310     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/msg.2002.122220     Document Type: Article

References (304)

1. Intracellular calcium its universal role as regulator
2. Calcium: Outside/inside homeostasis and signaling
3. Molecular and structural basis of target recognition by calmodulin
4. Three-dimensional structure of calmodulin
5. On biomineralization
6. Structure and function of voltage-gated ion channels
7. Membrane transport of small molecules and the ionic basis of membrane excitability
8. 2+ channels
9. Drug therapy: Calcium antagonist drugs
10. Voltage-gated ion channelopathies
11. Reducing calcium overload in the ischemic brain
12. Neuroprotective effects of gelsolin during murine stroke
13. Calcium signaling: A historical account, recent developments and future perspectives
14. ER calcium and the functions of intracellular organelles
15. Calcium signaling: An overview
16. NAADP: An emerging calcium signaling molecule
17. Capacitative calcium entry channels
18. Calmodulin: A prototypical calcium sensor
19. 2+/CaM-dependent kinases: From activation to function
20. Organization of early development by calcium patterns
21. 2+ sensing receptor from bovine parathyroid
22. Extracellular calcium sensing and extracellular calcium signaling
23. Homologs of an extracellular calcium/polyvalent cation-sensing receptor (CaR) are localized to the apical surface of specific epithelial cells in organs critical for ionic homeostasis in the elasmobranchs, Squalus erinacea, as well as teleosts, Pseudopleuronectes americanus and Onchorynchus and Fundulus herteroclitus
24. Identification of the sites of N-linked glycosylation on the human calcium receptor and assessment of their role in cell surface expression and signal transduction
25. Cation binding determinants of the calcium receptor revealed by functional analysis of chimeric receptors and a deletion mutant
26. The extracellular calcium receptor
27. Protein kinase C phosphorylation of threonine at position 888 in Ca2+-sensing receptor (CaR) inhibits coupling to Ca2+-store release
28. The many roles of the calcium-sensing receptor in health and disease
29. The calcium receptor and calcimimetics
30. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: Control of parathyroid cell growth via a calcium receptor
31. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism
32. 2+ (cation)-sensing receptor(s): One or many?
33. 2+ sensing receptor gene mutation
34. A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations
35. 2+ receptor-stimulated hormone release from sheep thyroid parafollicular cells
36. 2+-sensing receptor
37. Expression and signal transduction of calcium-sensing receptors in cartilage and bone
38. 2+ sensing receptor in cytotrophoblasts from human term placenta
39. Regulation of murine fetal-placental calcium metabolism by the calcium-sensing receptor
40. Optimal calcium intake
41. Homeostatic mechanisms regulating extracellular and intracellular calcium metabolism
42. Urinary excretion of calcium, magnesium, and phosphorus
43. Parathyroid hormone: Mechanism of action
44. Vitamin D: Photobiology, metabolism, mechanism of action, and clinical applications
45. The intestinal absorption of calcium, magnesium, and phosphate
46. Hyperparathyroid and hypoparathyroid disorders
47. Parathyroid cell proliferation in normal and chronic renal failure rats: The effects of calcium, phosphate, and vitamin D
48. Molecular mechanisms of secondary hyperparathyroidism
49. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracelluar calcium concentration in normal and abnormal parathyroid tissue
50. Calcium-regulated parathyroid hormone release in primary hyperparathyroidism
51. Dispersed cells prepared from human parathyroid glands: Distinct calcium sensitivity of adenomas vs primary hyperplasia
52. Individual parathyroid cells are more sensitive to calcium than a parathyroid cell population
53. A conserved cis-acting element in the parathyroid hormone 3′-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate
54. Parathyroid growth
55. Studies of the effects of 1,25-dihydroxyvitamin D on skeletal and calcium homeostasis and on inhibition of tumor cell growth
56. Endothelin receptor antagonist prevents parathyroid cell proliferation of low calcium diet-induced hyperparathyroidism in rats
57. Failure of thiazide diuretics to increase plasma calcium in mild primary hyperparathyroidism
58. Pathology and outcome of surgical treatment for lithium-associated hyperparathyroidism
59. Alterations in parathyroid dynamics in lithium-treated subjects
60. Investigation of calcium-induced hydrolysis of phosphoinositides in normal and lithium-treated parathyroid cells
61. Effect of lithium on incorporation of bromodeoxyuridine and tritiated thymidine into human parathyroid cells
62. Milk alkali syndrome associated with calcium carbonate consumption
63. An outbreak of hypervitaminosis D associated with the overfortification of milk from a home-delivery dairy
64. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative
65. Miscellaneous causes of hypercalcemia
66. Cancer-associated hypercalcemia: Morbidity and mortality
67. Die bedeutung der calciumbestimmung im blute fur die diagnose der niereninsuffzientz
68. Non-parathyroid hypercalcemia
69. Serum calcium, inorganic phosphorus and phosphatase activity in hyperparathyroidism, Paget's disease, multiple myeloma and neoplastic disease of the bones
70. Hypercalcemia in malignant disease without evidence of bone destruction
71. Humoral hypercalcemia of malignancy: A historical note
72. Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and non-humoral groups
73. Immunochemical characterization of circulating parathyroid hormoneBrelated protein in patients with humoral hypercalcemia
74. Hypercalcemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction
75. Development of a sensitive two-site immunoradiometric assay for parathyroid hormoneBrelated peptide: Evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma
76. Parathyroid hormoneBrelated protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer
77. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: Uncoupling of bone cell activity
78. Hypercalcemia and ectopic secretion of PTH by an ovarian carcinoma with rearrangement of the gene for PTH
79. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma
80. Hypercalcemia in gynecologic neoplasms
81. Addisonian crisis and hypercalcaemia
82. Endocrine causes of hypercalcemia other than primary hyperparathyroidism
83. Hypercalcemia due to granuloma-forming disorders
84. Hypercalcemia: Pathogenesis, clinical manifestations, differential diagnosis, and management
85. Age-dependent atrophy and microgravity travel: What do they have in common?
86. Immobilization
87. The hypercalcemic syndrome
88. Molecular pathology of parathyroid tumors
89. Molecular basis of primary hyperparathyroidism
90. Multiple endocrine neoplasia type I: Clinical features and management
91. Positional cloning of the gene for multiple endocrine neoplasia-type 1
92. New insights into the role of nuclear factor-kappa B in cell growth regulation
93. The tumor suppressor protein MENIN interacts with NF-kappa B proteins and inhibits NF-kappaB-mediated transactivation
94. Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11
95. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism
96. Multiple endocrine neoplasia type I: New clinical and basic findings
97. Heterogeneous size of the parathyroid glands in familial multiple endocrine neoplasia type 1
98. Findings and long-term result of parathyroid surgery in multiple endocrine neoplasia type 1
99. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
100. Multiple endocrine neoplasia type 2Bassociated RET proto-oncogene mutation do not contribute to the pathogenesis of sporadic parathyroid tumors
101. Multiple endocrine neoplasia type II
102. The molecular genetics of the multiple endocrine neoplasia syndromes
103. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: Linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas
104. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome
105. Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus
106. Genetic studies of a family with hereditary hyperparathyroidism-jaw tumor syndrome
107. Familial hyperparathyroidism without multiple endocrine neoplasia
108. Genetic screening for MEN1 mutations in families presenting with familial primary hyperparathyroidism (FIHP)
109. A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors
110. Alternative genetic pathways in parathyroid tumorigenesis
111. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor
112. Familial isolated hyperparathyroidism: A distinct genetic entity with an increased risk of parathyroid cancer
113. 2+ sensing receptor
114. Calcium-ionBsensing cell-surface receptors
115. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism: Effects of mutant gene dosage on phenotype
116. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs
117. PRAD1 (cyclin D1): A parathyroid neoplasia gene on 11q13
118. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice
119. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas
120. Multiple endocrine neoplasia type 1: Clinical and genetic features of the hereditary endocrine neoplasias
121. Absence of p53 point mutations in parathyroid adenoma and carcinoma
122. Patterns of chromosomal imbalances in parathyroid carcinomas
123. Genetic alterations in primary and secondary hyperparathyroidism
124. The extracellular calcium sensing receptor gene in human parathyroid tumors
125. Reduced Ca2+-receptor expression in parathyroid adenomas and uremic hyperparathyroidism
126. Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors
127. Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism
128. Dose-response relationships for radiation- induced hyperparathyroidism
129. Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy
130. The clinical syndrome of hyperparathyroidism
131. Further experience in diagnosis of hyperparathyroidism, including discussion of cases with minimal degree of hyperparathyroidism
132. Role of citric acid in primary hyperparathyroidism with renal lithiasis
133. Urinary excretion of calcium and magnesium in primary hyperparathyroidism
134. Nephrolithiasis in primary hyperpasrathyroidism
135. Nephrolithiasis in primary hyperparathyroidism
136. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis
137. Bone resorption by osteoclasts
138. Osteoprotegerin: A physiological and pharmacological inhibitor of bone resorption
139. Bone remodeling
140. Circulating levels of IL-6 are elevated in primary Hyperparathyroidism and correlate with markers of bone resorption
141. A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo
142. Osteoporosis, genetics and hormones
143. Therapeutic approaches to bone diseases
144. Skeletal disease in primary hyperparathyroidism
145. Markers of bone turnover in primary hyperparathyroidism
146. Cellular actions of parathyroid hormone on osteoblast and osteoclast differentiation
147. Effect of parathyroid hormone
148. Treatment of postmenopausal osteoporosis
149. Histomorphometric analysis of bone in primary hyperparathyroidism
150. Clinical course of primary hyperparathyroidism
151. Back pain and vertebral crush fractures: An unemphasized mode of presentation for primary hyperparathyroidism
152. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures
153. Fracture incidence in postmenopausal women with primary hyperparathyroidism
154. Primary hyperparathyroidism and peptic ulcer disease
155. Prevalence and causes of hypergastrinemia in primary hyperparathyroidism: A prospective study
156. Relationship of hyperparathyroidism to pancreatitis
157. Acute hypercalcemia causes acute pancreatitis and ectopic trypsinogen activation in the rat
158. Hypercalcemia causes acute pancreatic secretory block intracellular zymogen accumulation, and acinar cell injury
159. Neuromuscular disease in primary hyperparathyroidism
160. Clinical presentation of primary hyperparathyroidism
161. Hyperparathyroidism and the elderly
162. Coupling of calcium receptors to inositol phosphate and cyclic AMP generation im mammalian cells and Xenopus laevis oocytes and immunodetection of receptor protein by region-specific antipeptide antisera
163. "Limited" parathyroidectomy in geriatric patients
164. Death risk factor analysis in primary hyperparathyroidism
165. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure
166. Cardiovascular disease, interleukin-6, and risk of mortality in older women: The women's health and aging study
167. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease
168. Recent advances in the pathogenesis and therapy of uremic secondary hyperparathyroidism
169. The parathyroids in renal disease
170. Secondary hyperparathyroidism in renal failure: The trade-off hypothesis revisited
171. Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate
172. Renal osteodystrophy
173. Hyperparathyroidism in renal failure
174. Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure
175. The natural history and surgical treatment of hypercalcemia before and after renal transplantation
176. Parathyroid function in normocalcemic renal transplant recipients: Evaluation by calcium infusion
177. Tertiary hyperparathyroidism and refractory secondary hyperparathyroidism
178. Clinical review 122: Parathyroid carcinoma
179. Studies in a kindred with parathyroid carcinoma
180. Embryology, anatomy, and pathology of the parathyroids
181. Mitotic activity in benign parathyroid disease
182. Parathyroid cancer: The relationship of nuclear DNA content, clinical factors, and therapeutic strategies to clinical outcome
183. Flow Cytometric DNA Analysis of parathyroid tumors with special reference to its diagnostic and prognostic value in parathyroid carcinoma
184. Localization procedures in patients with persistent or recurrent hyperparathyroidism
185. The reasons for failure in parathyroid operations
186. Parathyroid re-exploration
187. Recurrent hyperparathyroidism
188. The reasons for persistent hypercalcemia after cervical exploration for presumed primary hyperparathyroidism
189. Subtotal parathyroidectomy in dialysis-dependent and post-renal transplant patients
190. Recurrent hyperparathyroidism due to parathyroid autografts: Incidence, presentation, and management
191. Results of surgical treatment of renal hyperparathyroidism
192. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type I patient
193. Parathyroid surgery in the multiple endocrine neoplasia type I syndrome: Choice of surgical procedure
194. Intraoperative parathormone measurement in patients with multiple endocrine neoplasia type I syndrome and hyperparathyroidism
195. Parathyroid mitogenic activity in plasma from patients with familial multiple endocrine neoplasia type 1
196. Recurrent hyperparathyroidism from benign neoplastic seeding: A review with recommendations for management
197. Parathyromatosis: A rare yet important cause of persistent or recurrent hyperparathyroidism
198. Hypercalcemic crisis
199. Hypercalcemic crisis
200. One hundred consecutive minimally invasive parathyroid explorations
201. Evaluation of the performance and clinical impact of a rapid intraoperative parathyroid hormone assay in conjunction with preoperative imaging and concise parathyroidectomy
202. Localization and operative management of undescended parathyroid adenomas in patients with persistent primary hyperparathyroidism
203. Localization studies in patients with persistent or recurrent hyperparathyroidism
204. Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent or persistent hyperparathyroidism
205. Prospective comparison of radionuclide, computed tomographic, sonographic and magnetic resonance localization of parathyroid tumors
206. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study)
207. Impact of technetium-99m-sestamibi localization of operative time and success of operations for primary hyperparathyroidism
208. Ultrasound and sestamibi scan as the only preoperative imaging tests in reoperation for parathyroid adenomas
209. Value of technetium 99m sestamibi iodine imaging in reoperative parathyroid surgery
210. Mechanism of technetium 99m sestamibi parathyroid imaging and the possible role of p-glycoprotein
211. Pre-operative localization and tissue uptake study in parathyroid imaging with technetium-99m-sestamibi
212. Prospective comparison of technetium 99m sestamibi iodine 123 radionuclide scan versus high-resolution ultrasonography for the preoperative localization of abnormal parathyroid glands in patients with hyperparathyroidism
213. Localization of parathyroid tumours in the minimally invasive era: Which technique should be chosen? Population-based analysis of 253 patients undergoing parathyroidectomy and factors affecting parathyroid gland detection
214. Hyperparathyroidism and pregnancy: A review
215. Risk of parathyromatosis after fine needle aspiration
216. Guidelines for the medical or surgical management of primary hyperparathyroidism
217. Primary hyperparathyroidism in the 1990s: Choice of surgical procedures for this disease
218. Clinical spectrum of primary hyperparathyroidism: Evolution with changes in medical practice and technology
219. Indications for surgery in patients with minimally symptomatic primary hyperparathyroidism
220. Consensus development conference statement
221. Osteoporosis and low bone mass in premenopausal and perimenopausal women
222. Vertebral osteopenia: A new indication for surgery in primary hyperparathyroidism
223. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism
224. Management of hyperparathyroidism in pregnancy
225. Primary hyperparathyroidism in pregnancy
226. Indications for parathyroidectomy and extent of treatment for patients with secondary hyperparathyroidism
227. Parathyroidectomy in chronic renal failure
228. Cutaneous necrosis from calcific uremic arteriolopathy
229. Calcific uremic arteriolopathy (calciphylaxis): An evolving entity?
230. Calciphylaxis in secondary hyperparathyroidism: Diagnosis and parathyroidectomy
231. Tumoral calcinosis: Controversies in the etiology and alternatives in the treatment
232. Surgical management of hyperparathyroidism
233. The anatomy of primary hyperparathyroidism
234. Minimally invasive parathyroidectomy for primary hyperparathyroidism: Decreasing operative time and potential complications while improving cosmetic results
235. Clinical usefulness of an intraoperative "quick parathyroid hormone" assay
236. Ambulatory parathyroidectomy for primary hyperparathyroidism
237. Undescended superior parathyroid gland: A potential cause of failed cervical exploration
238. Localization studies in patients with hyperparathyroidism
239. The use of high resolution ultrasound to locate parathyroid tumors during reoperations for primary hyperparathyroidism
240. Unilateral neck exploration for primary hyperparathyroidism
241. Success of unilateral neck exploration for sporadic primary hyperparathyroidism
242. Intraoperative measurement of parathyroid hormone in the surgical management of hyperparathyroidism
243. Late parathyroid function after successful parathyroidectomy guided by intraoperative hormone assay (QPTH) compared with the standard bilateral neck exploration
244. Unilateral neck exploration for primary hyperparathyroidism: Analysis of a controversy using a mathematical model
245. Minimally invasive parathyroid surgery
246. Endoscopic parathyroidectomy
247. Minimally invasive videoscopic parathyroidectomy by lateral approach
248. Minimally invasive video-assisted parathyroidectomy: Multi-institutional study
249. Clinical characteristics and surgical results in hyperparathyroidism caused by water-clear hyperplasia
250. Transplantation of the parathyroid glands in man: Clinical indications and results
251. The transplanted parathyroid gland: Evaluation of cryopreservation and other environmental factors which affect its function
252. The transplantation of parathyroid tissue in man: Development, ndications, technique, and results
253. New applications of total parathyroidectomy and autotransplantation: Use in proximal renal tubular dysfunction
254. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets
255. Subtotal parathyroidectomy vs total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: A randomized trial
256. Effect of calcitriol replacement on serum calcitonin and parathyroid hormone levels in CAPD patients
257. Subtotal parathryroidectomy in renal failure: Still needed after all these years
258. Calcium requirements in ESRD patients after total parathyroidectomy with autotransplantation
259. Intraoperative decay profile of intact
260. Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue
261. Persistent hyperparathyroidism caused by incomplete parathyroid resection and a hyperfunctioning parathyroid autograft
262. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1
263. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2
264. Results of heterotopic parathyroid autotransplantation: A 13-year experience
265. Natural history of parathyroid carcinoma
266. Surgical treatment of ten cases of parathyroid carcinoma: Importance of an initial en bloc tumor resection
267. Parathyroid carcinoma arising from parathyroid hyperplasia: Autoinfarction following intravenous treatment with pamidronate
268. Clinical course of metastatic parathyroid cancer
269. Surgical resection of metastatic parathyroid carcinoma
270. Localization and reoperation results for persistent and recurrent parathyroid carcinoma
271. Management of patients with persistent or recurrent primary hyperparathyroidism
272. Results of reoperations for persistent or recurrent secondary hyperparathyroidism in hemodialysis patients
273. Minimally invasive radio-guided parathyroidectomy in the reoperative neck
274. Intraoperative gamma probe localization of parathyroid adenomas
275. Screening for MEN1 mutations in patients with atypical endocrine neoplasia
276. Side localization of parathyroid adenomas by simplified intraoperative venous sampling for parathyroid hormone
277. Pre-operative localization and interventional treatment of parathyroid tumors: When and how?
278. Large vein sampling for intact parathyroid hormone in preoperative localization of enlarged parathyroid glands
279. Identification and management of intravagal adenoma
280. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay
281. Diagnostic strategies and surgical procedures in persistent or recurrent primary hyperaparathyroidism
282. Hypocalcemic emergencies
283. Parathyroid function in magnesium deficiency
284. Suppressibility of serum levels of PTH by calcium in the immediate postoperative period after surgery for primary hyperparathyroidism
285. Recovery of parathyroid hormone secretion after parathyroid adenomectomy
286. Effect of parathyroidectomy on the incidence of renal calculi
287. The effect of parathyroidectony on the recurrence of nephrolithiasis
288. Renal lithiasis and hyperparathyroidism: Diagnosis, management and prognosis
289. Hypercalciuria and recurrent urinary stone formation despite successful surgery for primary hyperparathyroidism
290. Renal stones and primary hyperparathyroidism: Natural history of renal stone disease after successful parathyroidectomy
291. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism
292. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism
293. Clinical manifestations of primary hyperparathyroidism before an after parathyroidectomy
294. IL-6 negatively regulates IL-11 production in vitro and in vivo
295. Maximal isokinetic muscle strength in patients with primary hyperparathyroidism before and after parathyroid surgery
296. Natural history of primary hyperparathyroidism
297. Parathyroidectomy in chronic renal failure: Short- and long-term results on parathyroid function, blood pressure and anemia
298. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy
299. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism
300. Assessment of patient outcomes after operation for primary hyperparathyroidism
301. A patient-based surgical outcome tool demonstrating improvement of symptoms following parathyroidectomy in patients with primary hyperparathyroidism
302. Effects of a parathyroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism